[1]蒋真斌,孙嘉.白细胞介素-17与骨质疏松[J].国际内分泌代谢杂志,2014,(02):103-105.[doi:10.3760/cma.j.issn.1673-4157.2014.02.009]
 Jiang Zhenbin*,Sun Jia.Interleukin-17 and osteoporosis[J].International Journal of Endocrinology and Metabolism,2014,(02):103-105.[doi:10.3760/cma.j.issn.1673-4157.2014.02.009]
点击复制

白细胞介素-17与骨质疏松()
分享到:

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
期数:
2014年02期
页码:
103-105
栏目:
骨代谢疾病专栏
出版日期:
2014-04-30

文章信息/Info

Title:
Interleukin-17 and osteoporosis
作者:
蒋真斌孙嘉
510282 广州,南方医科大学第二临床医学院(蒋真斌);510282 广州,南方医科大学珠江医院内分泌科(孙嘉)   
Author(s):
Jiang Zhenbin*Sun Jia.
*Second Medical School of Southern Medical University,Guangzhou 510282,China Corresponding author:Sun Jia,Email:nfmsj@126.com
关键词:
白细胞介素-17骨质疏松细胞因子
Keywords:
Interleukin-17OsteoporosisCytokines
DOI:
10.3760/cma.j.issn.1673-4157.2014.02.009
摘要:
白细胞介素-17(IL-17)是一种致炎细胞因子,参与了骨质疏松的发生及发展。IL-17可通过核因子-?资B受体活化因子(RANK)配体-RANK途径影响成骨细胞或破骨细胞的数量和活性;可降低骨保护素水平、诱导受体衔接蛋白合成,继而引起绝经后骨质疏松;干预胶原的合成与降解、与白细胞介素-32相互作用,进而诱导类风湿关节炎继发的骨质疏松;高血糖和瘦素可影响IL-17的水平进而影响糖尿病性骨质疏松的发展。因此,针对IL-17的治疗可为多种骨质疏松治疗提供新思路。
Abstract:
Interleukin-17(IL-17) is a proinflammatory cytokine,which takes part in the occurence and development of osteoporosis.IL-17 can not only influence the number and functions of osteoblasts or osteoclasts through ligand of receptor activator for nuclear factor -?资B(RANK)-RANK pathway,but also induce the postmenopausal osteoporosis through reducing the level of osteoprotegerin and increasing the synthesis of receptor interacting protein.IL-17 can also induce osteoporosis secondary to rheumatoid arthritis through affecting the synthesis and degradation of collagen or through its interaction with inter-leukin-32.Hyperglycemia and leptin can influence the level of IL-17 and then exert impact on the progres-sion of diabetic osteoporosis.So any treatment aiming at IL-17 will provide new therapies to various kinds of osteoporosis.

参考文献/References:

[ 1 ] Cua DJ,Tato CM.Innate IL-17-producing cells:the sentinels of the immune system[J].Nat Rev Immunol,2010,10(7):479-489. [ 2 ] Iwakura Y,Ishigame H,Saijo S,et al.Functional specialization of interleukin-17 family members[J].Immunity,2011,34(2):149-162. [ 3 ] Gaffen SL.Structure and signalling in the IL-17 receptor family[J].Nat Rev Immunol,2009,9(8):556-567. [ 4 ] Song X,Qian Y.The activation and regulation of IL-17 receptor mediated signaling[J].Cytokine,2013,62(2):175-182. [ 5 ] Horiuchi K,Kimura T,Miyamoto T,et al.Conditional inactivation of TACE by a Sox9 promoter leads to osteoporosis and increased granulopoiesis via dysregulation of IL-17 and G-CSF[J].J Immunol,2009,182(4):2093-2101. [ 6 ] DeSelm CJ,Takahata Y,Warren J,et al.IL-17 mediates estrogen-deficient osteoporosis in an Act1-dependent manner[J].J Cell Biochem,2012,113(9):2895-2902. [ 7 ] Tyagi AM,Srivastava K,Mansoori MN,et al.Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells:a new candidate in the pathogenesis of osteoporosis[J].PLoS One,2012,7(9):e44552. [ 8 ] Li N,Wang JC,Liang TH,et al.Pathologic finding of increased expression of interleukin-17 in the synovial tissue of rheumatoid arthritis patients[J].Int J Clin Exp Pathol,2013,6(7):1375-1379. [ 9 ] Gümüs P,Buduneli E,Biyiko?lu B,et al.Gingival crevicular fluid,serum levels of receptor activator of nuclear factor-kappa B ligand,osteoprotegerin,and interleukin-17 in patients with rheumatoid arthritis and osteoporosis and with periodontal disease[J].J Periodontol,2013,84(11):1627-1637.
[10] Fabbrini E,Cella M,McCartney SA,et al.Association between specific adipose tissue CD4+ T-cell populations and insulin resistance in obese individuals[J].Gastroenterology,2013,145(2):366-374.e1-e3.
[11] Won HY,Lee JA,Park ZS,et al.Prominent bone loss mediated by RANKL and IL-17 produced by CD4+ T-cells in TallyHo/JngJ mice[J].PLoS One,2011,6(3):e18168.
[12] Bai YD,Yang FS,Xuan K,et al.Inhibition of RANK/RANKL signal transduction pathway:a promising approach for osteo-porosis treatment[J].Med Hypotheses,2008,71(2):256-258.
[13] Yuan FL,Li X,Lu WG,et al.Type 17 T-helper cells might be a promising therapeutic target for osteoporosis[J].Mol Biol Rep,2012,39(1):771-774.
[14] Adamopoulos IE,Chao CC,Geissler R,et al.Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors[J]. Arthritis Res Ther,2010,12(1):R29.
[15] Ju JH,Cho ML,Jhun JY,et al.Oral administration of type-II collagen suppresses IL-17-associated RANKL expression of CD4+ T-cells in collagen-induced arthritis[J]. Immunol Lett,2008,117(1):16-25.
[16] Li X,Yuan FL,Lu WG,et al.The role of interleukin-17 in mediating joint destruction in rheumatoid arthritis[J].Biochem Biophys Res Commun,2010,397(2):131-135.
[17] Chabaud M,Lubberts E,Joosten L,et al.IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis[J].Arthritis Res,2001,3(3):168-177.
[18] Moon YM,Yoon BY,Her YM,et al.IL-32 and IL-17 interact and have the potential to aggravate osteoclastogenesis in rheumatoid arthritis[J].Arthritis Res Ther,2012,14(6):R246.
[19] Zhang S,Zhang Q,Zhang L,et al.Expression of ghrelin and leptin during the development of type 2 diabetes mellitus in a rat model[J]. Mol Med Rep,2012,7(1):223-228.
[20] Coppari R,Bj?rbaek C.Leptin revisited: its mechanism of action and potential for treating diabetes[J].Nat Rev Drug Discov,2012,11(9):692-708.
[21] Deselm CJ,Zou W,Teitelbaum SL.Halofuginone prevents estrogen-deficient osteoporosis in mice[J].J Cell Biochem,2012, 113(10):3086-3092.
[22] Colin EM,Asmawidjaja PS,van Hamburg JP,et al.1,25-dihydroxyvitamin D3 modulates Th17 polarization and inter-leukin-22 expression by memory T cells from patients with early rheumatoid arthritis[J].Arthritis Rheum,2010,62(1):132-142.
[23] Korczowska I,Lacki JK,Hrycaj P.Influence of infliximab on cytokines network and markers of bone remodeling in rheumatoid arthritis patients[J].Yonsei Med J,2013,54(1):183-188.
[24] Yago T,Nanke Y,Kawamoto M,et al.Tacrolimus potently inhibits human osteoclastogenesis induced by IL-17 from human monocytes alone and suppresses human Th17 differentiation[J].Cytokine,2012,59(2):252-257.

相似文献/References:

[1]姜艳,孟迅吾.雷尼酸锶防治骨质疏松的机制和临床研究[J].国际内分泌代谢杂志,2007,(04):247.
[2]郭丽婷,郝帅,高志红.2型糖尿病患者骨代谢生化指标和钙调激素 与骨密度关系的研究[J].国际内分泌代谢杂志,2015,(02):88.[doi:10.3760/cma.j.issn.1673-4157.2015.02.005]
 Guo Liting,Hao Shuai,Gao Zhihong..Research on the relationship between bone mineral density and biochemical index of bone metabolism ,calmodulin hormone in type 2 diabetic patients[J].International Journal of Endocrinology and Metabolism,2015,(02):88.[doi:10.3760/cma.j.issn.1673-4157.2015.02.005]
[3]尹飞,李菲,李志红.亚临床甲状腺功能异常与骨质疏松[J].国际内分泌代谢杂志,2015,(04):258.[doi:10.3760/cma.j.issn.1673-4157.2015.04.012]
 Yin Fei,Li Fei,Li Zhihong..Subclinical thyroid dysfunction and osteoporosis[J].International Journal of Endocrinology and Metabolism,2015,(02):258.[doi:10.3760/cma.j.issn.1673-4157.2015.04.012]
[4]王涛,马信龙.骨质疏松发病机制研究进展[J].国际内分泌代谢杂志,2014,(02):99.[doi:10.3760/cma.j.issn.1673-4157.2014.02.008]
 Wang Tao,Ma Xinlong..Research progress on pathogenesis of osteoporosis[J].International Journal of Endocrinology and Metabolism,2014,(02):99.[doi:10.3760/cma.j.issn.1673-4157.2014.02.008]
[5]田甜,沈山梅.肠促胰素与骨质疏松[J].国际内分泌代谢杂志,2016,36(05):320.[doi:10.3760/cma.j.issn.1673-4157.2016.05.09]
 Tian Tian,Shen Shanmei.Incretin and osteoporosis[J].International Journal of Endocrinology and Metabolism,2016,36(02):320.[doi:10.3760/cma.j.issn.1673-4157.2016.05.09]

备注/Memo

备注/Memo:
基金项目:广东省大学生创新实验计划项目(1212112014);广东省自然科学基金资助面上项目(S2012040006903) 通信作者:孙嘉,Email:nfmsj@126.com
更新日期/Last Update: 2014-03-20